ATRC
19.2.2024 19:39:33 CET | Business Wire | Press release
The UAE’s Advanced Technology Research Council (ATRC), mandated to shape an advanced R&D ecosystem in Abu Dhabi, signed a Memorandum of Understanding (MoU) with the Ministry Of Digital Technologies of the Republic of Uzbekistan, on the sidelines of the World Governments Summit (WGS) 2024. This synergy aims to leverage the technical expertise of ATRC and its subsidiaries for the seamless integration of Artificial Intelligence (AI) across Uzbekistan’s technological infrastructure and government services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240219748628/en/
His Excellency Shahab Issa Abu Shahab, Director General of ATRC and H.E. Sherzod Shermatov, Minister of Digital Technologies of Uzbekistan signing the Memorandum of Understanding on the sidelines of WGS 2024. (Photo: AETOSWire)
Under the terms of the agreement, Uzbekistan will explore and drive the adoption of Falcon LLMs and Falcon-powered solutions, as well as support the use of Falcon within its digital ecosystem across diverse use cases. Furthermore, Uzbekistan will encourage organizations and entities to join the recently announced ‘Falcon Foundation’ and contribute to the advancement of open-source Falcon models. The partnership marks a significant stride in exporting Falcon’s capability at a state level beyond the Middle East, laying the groundwork for global collaborative initiatives that will define the future of technological innovation.
Expressing optimism about the alliance, His Excellency Shahab Issa Abu Shahab, Director General of ATRC said: “The signing of this agreement underscores ATRC's steadfast dedication to forging global partnerships in the realm of AI. Collaborating closely with the government of Uzbekistan, we look forward to supporting the wider adoption of Falcon's pioneering solutions across diverse organizations within the country."
H.E. Sherzod Shermatov, Minister of Digital Technologies of Uzbekistan, said: “We are pleased to join forces with ATRC, in encouraging innovation as we integrate the state-of-the-art Falcon AI models into Uzbekistan’s technological infrastructure and government services. Our joint efforts are poised to fast-track innovation and help us overcome digital barriers to achieve our potential.”
Falcon LLM, a world-leading open-source AI model, is part of the Falcon series of powerful large language models developed by the Technology Innovation Institute (TII), ATRC’s applied research arm. ATRC and its commercialization arm VentureOne launched a pioneering AI company AI71 in November 2023 to deliver specialized AI models for clients – both companies and countries, while giving them the option of decentralized data ownership. Both TII and AI71 offer vital channels for the deployment of the Falcon series of LLMs.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240219748628/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom